Singapore markets close in 6 hours 46 minutes

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.79-0.28 (-2.78%)
At close: 04:00PM EDT
9.54 -0.25 (-2.55%)
After hours: 04:06PM EDT

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530
https://www.coherus.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees368

Key executives

NameTitlePayExercisedYear born
Mr. Dennis M. LanfearChairman, Pres & CEO1.86M4.26M1955
Mr. McDavid StilwellChief Financial Officer756kN/A1972
Mr. Vladimir Vexler Ph.D.Chief Scientific Officer778.28k843.84k1958
Mr. Bryan J. McmichaelSr. VP of Accounting, Principal Accounting Officer & Corp. ControllerN/AN/A1978
Mr. Richard L. HameisterChief Technical OfficerN/AN/AN/A
Mr. Christopher W. SlavinskyChief Bus. & Legal OfficerN/AN/A1973
Cheston TurbyfillVP of CommunicationsN/AN/AN/A
Ms. Karen KotzExec. VP of Sales & Strategic AccountsN/AN/AN/A
Ms. Rebecca SunshineChief HR OfficerN/AN/A1963
Mr. Michael A. FlemingChief Strategy OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Corporate governance

Coherus BioSciences, Inc.’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.